Asia biotech markets offer diverse opportunities

The temperature of Asian investment and pharma landscape took center stage at Biotech Showcase, an Informa event that runs concurrently with JPM. Panelists on the session “More Important than Ever: Opportunities in Asia,” discussed the various countries in the region including their capital markets, cultural dynamics, and evolving strategic partnerships.

Capital markets and funding

Asia’s capital markets are as diverse as its countries, offering a mix of opportunities and risks. China, for instance, has emerged as a powerhouse in innovation, driven by a robust capital market and government support. However, the closure of China’s IPO market for biotech companies without revenue has created funding bottlenecks. 

“In 2023, many biotech companies struggled to secure licensing deals due to limited private funding,” Echo Hindle-Yang, founder & CEO of MSQ Ventures, added. This has forced companies to explore alternative funding sources, including public markets and international investors.

Japan, on the other hand, has a smaller venture capital community but is witnessing growth due to government initiatives. “Japan’s government is actively supporting basic science into medicine, creating opportunities for startups to mega-pharmas,” said Ken-ichiro Kuninobu, co-founder and CEO of FELIQS. 

Despite these efforts, Japan’s IPO market remains limited, with company valuations often capped at $200 million, but usually around $60 million, restricting large-scale investments.

South Korea stands out for its government-backed funding initiatives, such as the Korean Drug Development Fund, which aims to invest up to $2 billion in biotech projects by 2030. “Korea’s government has created a massive VC community, fueling a booming biotech era,” said Minji Kim, entrepreneur in residence at Formation Bio.

Cultural dynamics

Cultural differences across Asia significantly impact deal-making, talent acquisition, and innovation. China’s entrepreneurial spirit and risk-taking culture have propelled it to the forefront of biotech innovation. “China’s work ethic and execution speed are unmatched,” said Kim. 

Japan, in contrast, adopts a methodical and consensus-driven approach. “Japan is a very different model,” said Kim. “Historically, Japan has a very sophisticated pharma industry … the leader of Asian countries.” She also noted that Japan is very methodical, slow and consensus driven yielding high-quality science, which may be viewed as less entrepreneurial. However, she added, “Japan’s focus on durability and systemic responsibility makes it a reliable partner for long-term collaborations.”

South Korea strikes a balance between speed and quality, leveraging government support and a strong manufacturing base. “Korea is known for biologics manufacturing, with companies like Samsung Biologics and Celltrion leading the way,” Kim added. The country’s cultural mentality of rapid execution is complemented by a deep foundation for innovation.

Risk-benefit

While Asia offers immense financial opportunities, there are risks. Regulatory hurdles, geopolitical tensions, and cultural misunderstandings can derail investments. “Taking Chinese investment requires caution due to U.S.-China tensions and regulatory issues like CFIUS (The Committee on Foreign Investment in the United States),” said Art Tappas, CEO of Tappas Capital. “You need to ensure all filings are in order to avoid complications.”

However, other panelists maintained the benefits are too great to ignore.

“Asia’s strengths in genomics, AI, and aging population initiatives are driving innovation,” Nav Khosla, partner, with Novo Holdings Asia, observed. “Companies that fail to engage with Asia risk falling behind.”

Theresa Heah, CEO, Eyexora, agreed: “If you’re not in China or other parts of Asia, you’re lagging behind. Asia is the future.”